Skip to content

Not medical advice. Talk to your provider before using any peptide. Full disclaimer

SS-31 (Elamipretide) peptide icon, one bubble per amino acidSS-31 (Elamipretide)4 residuesRYKFEach bubble = one amino acid. Size = residue mass. Color = chemical class.

SS-31 (Elamipretide)

Beginner tier: 4 mg, daily · community consensus

Anti-AgingFDA Approved
4 h half-life·Injection

Also known as: SS-31, MTP-131, Bendavia

FDA accelerated approval came through September 2025, making elamipretide one of only a handful of mitochondrial-targeted drugs to reach the market. SS-31 (brand name FORZINITY, also known as elamipretide, MTP-131, or Bendavia) is a four-amino-acid peptide that crosses into mitochondria and binds cardiolipin, a lipid that holds the electron transport chain together. The TAZPOWER trial earned approval based on knee extensor strength gains in Barth syndrome patients, though the randomized-phase primary endpoints were not met. Longevity researchers and biohackers now use SS-31 at community-derived doses between 2 and 10 mg daily for energy, recovery, and mitochondrial support.

What Is SS-31 (Elamipretide)?

Four amino acids. That is all SS-31 is. D-Arg-dimethylTyr-Lys-Phe-NH2, a tetrapeptide small enough to cross cell membranes without relying on mitochondrial membrane potential. It concentrates more than 1,000-fold inside mitochondria and locks onto cardiolipin, the phospholipid that anchors cytochrome c to the inner mitochondrial membrane.

SS-31 (elamipretide, CAS 736992-21-5, also called MTP-131 and Bendavia) earned FDA accelerated approval in September 2025 under the brand name FORZINITY (NDA 215244) for Barth syndrome in patients weighing at least 30 kg. The approval rested on open-label extension data from the TAZPOWER trial (n=12)[1], where knee extensor strength improved 42% from baseline at 168 weeks. The randomized-phase primary endpoints, 6-minute walk test and total fatigue score, were not met in the initial 12-week crossover.

Mechanistic evidence is strong. Cardiolipin oxidation collapses cristae, slows electron transfer between complexes III and IV, leaks electrons into superoxide, and drops ATP output. SS-31 prevents that peroxidation; it stabilizes cristae architecture and restores electron flow at the source rather than scavenging free radicals after they form. Preclinical models show reversed age-related cardiac dysfunction [2], improved renal filtration, and neuroprotection from ischemia-reperfusion injury.

The longevity community has adopted SS-31 at doses between 2 and 10 mg daily, well below the 40 mg FDA-approved dose. No dose-finding trial exists in healthy adults, so these community doses are pragmatic cost and tolerability decisions rather than clinically validated thresholds. Reports from roughly 50 to 100 threads across r/Peptides, r/longevity, and r/Nootropics describe subtle energy gains, better exercise recovery, and reduced fatigue. Injection site reactions affect nearly all users.

How SS-31 (Elamipretide) Works

SS-31 is a cell-permeable tetrapeptide with an alternating aromatic-cationic motif. That structure lets it cross lipid bilayers without needing mitochondrial membrane potential as a driving force. Once inside the cell, it accumulates more than 1,000-fold within mitochondria.

The target is cardiolipin. This anionic phospholipid sits exclusively on the inner mitochondrial membrane, where it anchors cytochrome c and holds the electron transport chain complexes in their functional supercomplex arrangements. When cardiolipin oxidizes (a consistent hallmark of aging and mitochondrial disease), cristae flatten out. Electron transfer between complexes III and IV slows. Electrons leak sideways to form superoxide. ATP production falls.

SS-31 binds directly to cardiolipin and blocks peroxidation. Cristae architecture stays intact. Electron flow through the ETC normalizes. Reactive oxygen species drop at the point of generation, not downstream. The result: improved ATP synthesis, preserved mitochondrial membrane potential, and blocked cytochrome c release, which prevents the intrinsic apoptosis cascade.

In aged mice, 8 weeks of SS-31 reversed cardiac diastolic dysfunction and improved contractile reserve [2]. The TAZPOWER open-label extension [1] tracked 12 Barth syndrome patients for 168 weeks and confirmed sustained functional improvements. MMPOWER-3 (n=218)[3] tested SS-31 in primary mitochondrial myopathy; the overall primary endpoint was not met, though a nDNA-variant subgroup showed gains on the 6-minute walk test.

SS-31 (Elamipretide) Benefits

  • SS-31 benefits center on mitochondrial protection and cellular energy restoration.
  • Cardiolipin stabilization at the source. SS-31 prevents the lipid peroxidation that collapses cristae and disrupts electron transport, targeting aging where it starts.
  • 42% knee extensor strength increase at 168 weeks in the TAZPOWER open-label extension (n=12 Barth syndrome patients)[1].
  • Heart protection in preclinical models. Eight weeks of SS-31 reversed diastolic dysfunction in aged mice, restoring cardiac function to near-young levels [2].
  • Improved exercise recovery reported consistently across community users at 4 to 10 mg daily, with reduced post-workout fatigue and better tolerance during training.
  • ROS reduction at the electron transport chain rather than downstream scavenging; a mechanistic advantage over conventional antioxidants like vitamin C or CoQ10.
  • Renal protection in preclinical ischemia-reperfusion models, preserving glomerular filtration through mitochondrial stabilization in kidney tubular cells.

SS-31 (Elamipretide): Science vs Community Consensus

Partially Aligned
Scientific Evidence
Moderate
Based on 8 key studies·FDA-approved

FDA accelerated approval granted September 19, 2025 (NDA 215244, FORZINITY) for Barth syndrome: based on open-label extension knee extensor strength improvement, NOT the randomized phase endpoints.

Dosing studied: 40 mg SC once daily (FDA-approved for Barth syndrome); 20 mg for severe renal impairment (eGFR <30, not on dialysis)
Read the evidence (key study, limitations)

The 12-week RCT crossover primary endpoints (6-minute walk test, total fatigue score) were NOT met. MMPOWER-3 Phase 3 (primary mitochondrial myopathy) also failed primary endpoint in the overall population; nDNA-variant subgroup showed 6MWT improvement. No FDA approval for HFpEF or any other indication as of October 2026 (Drugs@FDA). Mechanistic evidence is very strong (cardiolipin stabilization, ROS reduction, ETC restoration). No dose-finding trial in healthy adults exists.

Key Study

PMID 38602181: TAZPOWER 168-week open-label extension (Barth syndrome, n=12); PMID 37268435: MMPOWER-3 Phase 3 (PMM, n=218)

Limitations

Accelerated approval contingent on confirmatory trial verifying clinical benefit. Primary RCT phase of TAZPOWER missed both endpoints. MMPOWER-3 failed overall primary endpoint. All trials conducted in disease populations (Barth syndrome, PMM, HFpEF): no RCT in healthy aging adults. Community doses (1–20 mg) are 2–40× below the studied 40 mg clinical dose with no head-to-head data. Long-term safety beyond 168 weeks unstudied. Phase 3 trial sizes are small (n=12–218) due to orphan-disease context.

Community Experience
Weak
3.5/5
Based on ~50–100+ threads estimated across r/Peptides, r/longevity, r/Nootropics

Niche but growing.

Community dosing: 0.5–2 mg/day (conservative start); 4–10 mg/day (community standard); up to 20 mg/day (advanced)
Read the reports (what users report 5, common issues 5)

Primarily used by longevity/biohacking community for energy, fatigue, and exercise recovery. Reports are cautiously positive. Major barriers: dose uncertainty (0.5 mg vs 40 mg), high cost, and injection site reactions in virtually all users. Community consensus has converged around 4–10 mg/day as the "standard" research dose, with some beginning at 500 mcg–2 mg.

What users report (5)
  • Reduced fatigue and improved baseline energy levels
  • Better exercise recovery and reduced post-workout soreness
  • Subtle improvements in exercise tolerance and endurance
  • Anecdotal cognitive clarity and reduced brain fog
  • Perceived anti-aging / longevity "insurance" use case
Common issues (5)
  • Injection site erythema, pain, and induration (100%, 75%, 67% in TAZPOWER: very high incidence)
  • Eosinophilia in majority of users during first 90 days (usually asymptomatic but can be alarming on CBC)
  • Cost: research-grade $50–$80 per 10 mg vial; 10 mg/day = $150–$240/month minimum
  • Dose ambiguity: community uses 4–10× lower than the only studied clinical dose (40 mg)
  • No perceived effect is common early; mitochondrial improvements may not be subjectively noticeable
Partially Aligned

Science and community agree on the mitochondrial-cardiolipin mechanism. The FDA-approved 40 mg dose reflects a serious disease population; community extrapolates a lower minimum effective dose for healthy aging adults without supporting trial data. Neither confirmed nor refuted: data gap, not contradiction.

SS-31 (Elamipretide) Dosage Guide

CommunityBeginner and moderate tiers are community doses of 4-10 mg SC daily, from research-grade powder mixed with BAC water. The aggressive tier is the FORZINITY label dose, 40 mg SC once daily for Barth syndrome in patients 30 kg and up. FORZINITY is a ready-to-use 80 mg/mL solution, so 40 mg is 0.5 mL with nothing mixed in (label sections 2.1, 3 and 11).Source (opens in a new tab)
LevelDose / InjectionFrequency
Beginner4 mg
DailyTrack
Moderate10 mg
DailyTrack
Aggressive40 mgThis is the FORZINITY label dose for Barth syndrome in patients 30 kg and up (label section 2.1). FORZINITY is a ready-to-use 80 mg/mL solution, so 40 mg is 0.5 mL drawn straight from the vial with nothing added (sections 3 and 11). SS-31 vial and BAC water math applies to research-grade powder only.
DailyTrack
Note:

Reconstitution math first, for research-grade powder vials. A 10 mg vial with 1 mL bacteriostatic water gives you 10 mg/mL. At that concentration, 4 mg equals 40 units on a U-100 insulin syringe (0.4 mL). A 10 mg dose takes the full syringe (100 units, 1.0 mL). For the 40 mg vial, add 4 mL BAC water for the same 10 mg/mL concentration; 10 mg is still 100 units, but you get four doses per vial instead of one.

FORZINITY, the FDA-approved product, skips all of this. It is a ready-to-use 80 mg/mL solution in a 280 mg/3.5 mL vial (label section 3). Its 40 mg dose is 0.5 mL, drawn with the syringe your healthcare provider prescribes (sections 2.1 and 11, Instructions for Use).

Morning dosing is the community standard. There is no meal timing requirement.

You'll want to pre-treat injection sites. Cetirizine 10 mg taken 30 minutes before your shot makes a real difference for the first few weeks. Rotate between abdomen and upper thigh, and inject slowly. The site reactions are the number one reason people quit early.

Get a CBC at baseline and again at week 8. The eosinophilia is expected, but you want a record showing it was absent before you started.

No published stability data exist for reconstituted research-grade SS-31. Community reports keep sealed powder at -20°C and the mixed vial at 2-8°C for up to 28 days. Keep unopened FORZINITY vials at 2-8°C and never freeze them. After the first dose, an opened vial can stay at 2-8°C or at 20-25°C; discard it 8 days after first opening (label section 16.2).

Calculate your SS-31 (Elamipretide) dose
Free dosage calculator with syringe visualization

Or use the universal Peptide Calculator for any peptide.

SS-31 (Elamipretide) Protocols by Goal

beginnerCommunity12 weeks; optional 4-week break then repeat (community cost-cycling)
Titration
Wk 1–2
2 mg · Daily · SubQ
Maintenance
Wk 3–12
4 mg · Daily · SubQ

Expected: Modest improvement in energy and exercise recovery by weeks 4–6. Effects are subtle at this dose range: no clinical RCT data supports efficacy at 4 mg in healthy adults.

Monitor: Optional CBC at baseline and week 8 to monitor for eosinophilia. No other formal monitoring required for healthy adults at this dose.

How to Inject SS-31 (Elamipretide)

  1. 1
    Step 1

    Wash hands thoroughly and clean the vial stopper with an alcohol swab.

  2. 2
    Step 2

    Research-grade powder only: draw bacteriostatic water into a syringe. Use 1 mL for a 10 mg vial (gives 10 mg/mL) or 4 mL for a 40 mg vial (same 10 mg/mL concentration). Inject water down the side of the vial, not directly onto the powder.

  3. 3
    Swirl gently until dissolved

    SS-31 dissolves quickly. Do not shake.

  4. 4
    Step 4

    Draw your dose of mixed research-grade powder with a U-100 insulin syringe (29 or 30 gauge, 0.5 inch needle). At 10 mg/mL: 20 units equals 2 mg, 40 units equals 4 mg, 100 units equals 10 mg. FORZINITY is a ready-to-use 80 mg/mL solution with nothing to mix or swirl. Draw the prescribed dose in mL, using only the syringe your healthcare provider prescribes. 40 mg is 0.5 mL (label sections 2.1 and 11, Instructions for Use).

  5. 5
    Step 5

    Clean the injection site (abdomen or upper thigh) with an alcohol swab. Let dry.

  6. 6
    Pinch skin and insert needle at a 45 to 90 degree angle

    Inject slowly over 30 to 60 seconds. Slow injection reduces site reactions.

  7. 7
    Rotate injection sites each day

    Alternate between left abdomen, right abdomen, left thigh, and right thigh.

  8. 8
    Step 8

    Research-grade powder: store the mixed vial at 2-8°C (a standard refrigerator) and use it within 28 days. That figure comes from community reports; no published stability data exist for reconstituted research-grade SS-31. FORZINITY: keep an opened vial at 2-8°C or 20-25°C and discard it 8 days after first opening (label section 16.2).

  9. 9
    Dose timing: morning, same time each day

    No food restriction required.

Mixing your own vial? Use the SS-31 (Elamipretide) reconstitution calculator for the exact BAC-water-to-mcg math on any vial size.

SS-31 (Elamipretide) Stacking Protocols

Works With

Avoid

MitoQ / Mitoquinol mesylate

Both target the inner mitochondrial membrane. Overlapping mechanism may produce unpredictable additive effects on membrane dynamics; no formal interaction studies.

Cyclosporine A

Cyclosporine inhibits mPTP (mitochondrial permeability transition pore): overlapping mechanism with SS-31 cardiolipin stabilization. Combined effects unpredictable; no interaction data.

Anthracycline chemotherapeutics (doxorubicin, daunorubicin)

SS-31 mitochondrial protection may mask early cardiotoxicity signals from anthracyclines. Concurrent use requires close cardiac monitoring.

Do not combine

Estimated Cost

Brand Price
FORZINITY (elamipretide HCl injection): Stealth BioTherapeutics; orphan drug pricing not publicly disclosed; estimated $50,000–$200,000+/year for clinical use in Barth syndrome (US orphan drug range)
Generic / Research
Not available: recently approved (Sept 2025); no generic pathway established
Compounded
Research-grade: $50–$80 per 10 mg vial; 40 mg vials also exist. At 10 mg/day: ~$1,500–$2,400/month (10 mg vials) or significantly lower per-mg cost with 40 mg vials.

Pricing updated 2026-04-09

SS-31 (Elamipretide) Side Effects

Injection site reactions are the defining tolerability challenge with SS-31. In the TAZPOWER trial [4], 100% of participants developed injection site erythema. 75% reported pain. 67% experienced induration. These numbers are not typical for subcutaneous peptides. Community reports confirm the clinical data: redness, swelling, and a firm lump at the injection site are expected, not exceptional.

Site rotation between abdomen and upper thigh helps. Reactions typically moderate after 2 to 4 weeks of consistent use. Topical 1% hydrocortisone cream or oral cetirizine 10 mg before injection can reduce severity. Injecting slowly over 30 to 60 seconds also helps based on community experience. If induration expands, feels warm, or shows discharge, stop and evaluate for sterile abscess.

Eosinophilia is the second major concern. Raised eosinophil counts are common after 30 or more days of SS-31, with levels peaking around day 90. This shows up on a CBC and can be alarming if unexpected. In elamipretide trials, the rise was not linked to symptoms or other lab changes. Counts returned to baseline after 6 to 12 months of continued use, or after stopping (section 6.1). Do not discontinue solely for isolated eosinophilia without symptoms. If wheeze, GI distress, rash, or other organ-specific symptoms appear alongside raised eosinophils, stop SS-31 and consult a physician immediately.

The FORZINITY label carries two warnings (section 5). The first is allergic reactions, including serious ones that needed emergency care, with rash, papular lesions, eczematous dermatitis or cough (section 5.2). They can start anywhere from minutes to months after the first dose.

At any sign of an immediate allergic reaction, stop and get medical help right away (section 17). After a serious reaction, the label says not to restart it. Mild to moderate skin reactions can be treated with a topical corticosteroid and an oral antihistamine, though persistent or severe ones may mean stopping.

The second warning is benzyl alcohol. FORZINITY contains 20 mg/mL as a preservative, and the label says "Do not use in neonates" (section 5.1). Serious and fatal reactions have been reported in low-birth-weight and preterm newborns given benzyl alcohol-containing drugs intravenously (sections 5.1 and 8.4).

Pregnancy and breastfeeding are not contraindications on the FORZINITY label (section 4). Barth syndrome is unlikely to affect females, so there are no data in pregnant women and the risk of birth defects or miscarriage is unknown. Rat and rabbit studies found no harm to development at any dose tested (section 8.1).

No data show whether FORZINITY reaches breast milk or affects a breastfed infant. The label weighs breastfeeding's benefits against the mother's need for the drug and any possible harm to the infant (section 8.2). All of this describes FORZINITY; research-grade SS-31 powder is a different product with no safety testing of its own. The MMPOWER-3 trial excluded pregnant or breastfeeding women and required highly effective birth control for women who could become pregnant (NCT03323749).

Two cautions here come from research, not the FORZINITY label. People with active cancer should avoid SS-31, since no carcinogenicity studies exist (section 13.1) and MMPOWER-3 excluded active cancer (NCT03323749). That trial also excluded most active cardiac conduction abnormalities, so safety in that group is unknown.

Renal impairment matters. SS-31 is renally excreted. The FDA label calls for dose reduction to 20 mg daily for severe renal impairment (eGFR under 30, not on dialysis). Baseline renal function should be checked before starting.

Long-term safety beyond 168 weeks has not been characterized. Community users running sub-clinical doses (2 to 10 mg) have less safety data coverage than trial participants at 40 mg. Lower doses likely carry lower risk, but this assumption lacks trial validation.

Common Issues & Solutions

Injection site reactions (erythema, pain, induration): Expected in nearly all users. Apply topical 1% hydrocortisone cream or take cetirizine 10 mg before injection. Reactions typically improve after 2–4 weeks with consistent site rotation (abdomen and upper thigh alternating).

Eosinophilia on CBC: Common after 30+ days; peaks ~day 90. In elamipretide trials, counts returned to baseline after 6 to 12 months of use or after stopping (label section 6.1). Do not discontinue unless accompanied by organ-specific symptoms (wheeze, GI distress, rash). Counts may still be raised at week 16, so repeat the CBC later to track the trend.

No perceived effect at community doses (1–10 mg): Common. Mitochondrial improvements may manifest as subtle energy and recovery changes rather than dramatic subjective effects. Clinical benefit at sub-40 mg doses is not RCT-proven in healthy adults: track objective metrics (exercise performance, HRV, fatigue scores).

High cost / supply interruption: research-grade supply can end partway through a cycle.

Dose confusion (0.5 mg vs 10 mg vs 40 mg): Community uses 0.5–20 mg; the only clinical trial dose was 40 mg/day in disease populations. No validated minimum effective dose for healthy adults. Lower community doses are pragmatic cost/tolerability decisions: not clinically validated efficacy thresholds.

Ask AI about this page

Ask AI for a second opinion on SS-31 (Elamipretide) dosing and side effects

Contraindications

  • Serious hypersensitivity to elamipretide or any FORZINITY excipient: the one contraindication on the FORZINITY label (section 4). Serious allergic reactions needing emergency care have occurred, from minutes to months after starting, and the label says not to restart after one (section 5.2)
  • Pregnancy and breastfeeding: not a contraindication on the FORZINITY label. The label has no data in pregnant women, so the risk of birth defects or miscarriage is unknown. In rat and rabbit studies, no harm to development occurred at any dose tested (section 8.1). No data show whether it reaches breast milk or affects a breastfed infant. The label weighs breastfeeding's benefits against the mother's need for FORZINITY and any possible harm to the infant (section 8.2). These findings come from FORZINITY's label; research-grade powder is a different product with no safety testing of its own. The MMPOWER-3 trial excluded pregnant or breastfeeding women and required highly effective birth control for women who could become pregnant (NCT03323749)
  • Severe renal impairment: a dose change, not a contraindication on the FORZINITY label. FORZINITY's dose is halved to 20 mg once daily for adults with eGFR under 30 mL/min who are not on dialysis (sections 2.2 and 8.6). Mild or moderate impairment needs no change. There is no labelled dose for adults on dialysis or for children with renal impairment. Elamipretide is excreted in the urine; exposure rose 125% in severe impairment (section 12.3)
  • Children under 30 kg: safety and effectiveness have not been established (section 8.4). The label dose is for patients 30 kg and up (section 2.1)
  • Newborns: the label says "Do not use in neonates" (section 5.1). FORZINITY contains 20 mg/mL benzyl alcohol as a preservative. Serious and fatal reactions, including gasping syndrome, have been reported in low-birth-weight and preterm newborns given benzyl alcohol-containing drugs intravenously (sections 5.1 and 8.4)
  • Active malignancy or history of cancer: a research caution, not on the FORZINITY label. No carcinogenicity studies have been done (label section 13.1), and MMPOWER-3 excluded active cancer or cancer within the past 2 years (NCT03323749)
  • Severe cardiac conduction abnormalities: a research caution, not on the FORZINITY label. MMPOWER-3 excluded most active conduction abnormalities (NCT03323749), so safety in this group is not established

Drug Interactions

  • Anthracycline chemotherapeutics (doxorubicin, daunorubicin): SS-31 may mask early signs of cardiotoxicity by protecting mitochondria; monitor cardiac function closely if co-administered
  • Other mitochondrial-targeted compounds (MitoQ, CoQ10, idebenone): no formal interaction studies; theoretical additive effects on mitochondrial membrane dynamics
  • Immunosuppressants (cyclosporine A): cyclosporine inhibits mitochondrial permeability transition pore opening, which overlaps with SS-31 mechanism; potential for unpredictable combined effects
  • Insulin and oral hypoglycemics: while SS-31 does not directly affect glucose metabolism, improved mitochondrial function may alter insulin sensitivity; monitor blood glucose
  • Anticoagulants: no known pharmacokinetic interaction, but as with all subcutaneous injectables, monitor for injection site bruising

Product Quality

Recommended Monitoring

TestWhenTarget
CBC with differentialBaseline, then at week 8 and week 16Eosinophils <500 cells/μL (normal); mild elevation 500–1,500/μL acceptable if asymptomatic; >1,500/μL investigate for organ involvement
Renal function panel (BMP or CMP)Baseline; repeat at week 12 if any renal compromise or for long-term continuous useeGFR ≥30: no dose change for mild or moderate impairment; eGFR <30 and not on dialysis: half dose (label: 20 mg/day); on dialysis: no labelled dose
Injection site visual assessmentEach injection cycle: inspect prior site before next injectionNot listed
CBC with differential

Eosinophilia is common after 30 or more days of SS-31 use and peaks around day 90. In elamipretide trials, counts returned to baseline after 6 to 12 months of use or after stopping (label section 6.1). Monitor the trend and rule out eosinophilic organ involvement.

Renal function panel (BMP or CMP)

Elamipretide is excreted in the urine (section 12.3). The FDA label halves its 40 mg dose to 20 mg/day below eGFR 30 mL/min without dialysis. It gives no dose for dialysis (sections 2.2 and 8.6)

Injection site visual assessment

Near-universal injection site reactions; expanding induration, warmth, or purulent discharge may indicate sterile abscess or infection requiring intervention

SS-31 (Elamipretide) Before and After

Weeks 1-2

SS-31 begins accumulating in mitochondrial membranes. Cardiolipin stabilization starts at the molecular level. Most users notice no outward changes yet. Injection site reactions (redness, mild soreness) are the most common early experience.

Weeks 3-4

Mitochondrial ETC efficiency begins to improve. Some individuals report subtle increases in baseline energy and reduced fatigue during daily activities. ROS production at the inner membrane decreases measurably in preclinical models at this timepoint.

Weeks 5-8

Clinical trial data shows measurable improvements in 6-minute walk test distance and reduced fatigue scores in Barth syndrome patients during this window. Users may notice improved exercise tolerance, better recovery from physical exertion, and more consistent energy throughout the day.

Weeks 9-12

Continued improvement in mitochondrial function. Cardiac parameters such as stroke volume and cardiac output showed improvement in open-label extension studies. Skeletal muscle strength and endurance gains become more noticeable.

Weeks 12-24+

Long-term open-label data (up to 168 weeks in TAZPOWER) showed sustained improvements in cardiac and functional outcomes. Protocol duration beyond 12 weeks should be guided by a physician. Long-term safety beyond clinical trial settings is not fully established.

What to Expect

Weeks 1 to 2, Titration and Tolerance Assessment: Cardiolipin binding begins at the molecular level during this window. Electron transport chain stabilization starts, but nothing measurable shows up clinically. Most users notice zero benefits. Injection site reactions dominate the experience, with near-universal redness, pain in about 75% of users, and induration in roughly 67%. This is normal, not a reason to quit.

Weeks 3 to 6, Early Mitochondrial Adaptation: Preclinical models show measurable ROS reduction and improved ATP synthesis by this point. Some users pick up on subtle energy improvements and better exercise tolerance. Post-workout fatigue may ease modestly. Injection site reactions start moderating if you are rotating sites. Eosinophilia begins appearing on CBC after 30 days of use; it is typically asymptomatic.

Weeks 6 to 12, Functional Improvement Window: The TAZPOWER open-label extension recorded 16% improvement in 6-minute walk test distance and 19% improvement in fatigue scores by week 12. Knee extensor strength gained 30% from study baseline. Community users report more consistent daily energy, improved exercise performance, and better recovery. Some describe cognitive clarity. Eosinophils peak around day 90 and then begin normalizing.

Weeks 12 to 24, Sustained Benefit and Stabilization: By week 36 of TAZPOWER, improvements reached 25% on the 6-minute walk test, 26% for fatigue scores, and 42% for knee extensor strength (all open-label data). Community users who continue past 12 weeks report maintained benefits. Cost fatigue leads many to take a planned break or drop to lower maintenance dosing. Eosinophil counts may still be raised. In elamipretide trials, they returned to baseline after 6 to 12 months of use or after stopping.

Weeks 24 to 168 and beyond, Long-Term Maintenance: The TAZPOWER 168-week open-label extension showed sustained cardiac and functional improvements with no new safety signals in Barth syndrome patients. Long-term community data is sparse. Most people cycle for cost reasons rather than biological necessity. Benefits appear maintained in those who continue. Long-term safety in healthy aging adults has not been characterized beyond the clinical trial population.

Detailed Timeline: Science vs Community

Weeks 1–2
Science

Cardiolipin binding begins; ETC structural stabilization starts at molecular level. No measurable functional changes detectable clinically this early.

Community

Most users report no noticeable benefits. Injection site reactions are the dominant early experience.

Weeks 3–6
Science

Preclinical models show measurable ROS reduction and improved ATP synthesis at this timepoint. Eosinophilia begins to appear on CBC (>30 days of use).

Community

Subtle energy improvements reported by some users. Better exercise tolerance and modest reduction in post-workout fatigue. Injection site reactions begin to moderate with site rotation.

Weeks 6–12
Science

TAZPOWER open-label extension: 16% improvement in 6MWT and 19% improvement in fatigue scores by week 12; knee extensor strength +30% from study baseline.

Community

More consistent daily energy, improved exercise performance, better recovery. Some report cognitive clarity. Peak eosinophilia around day 90.

Weeks 12–24
Science

TAZPOWER week 36: 25% improvement in 6MWT, 26% fatigue improvement, 42% knee extensor strength increase from study baseline (open-label data).

Community

Maintained benefits. Cost fatigue leads many to take a planned break or transition to lower maintenance dosing.

Weeks 24–168+
Science

TAZPOWER 168-week open-label extension showed sustained cardiac and functional outcome improvements with no new safety signals.

Community

Long-term community data is sparse. Most cycle for cost reasons rather than safety. Benefits appear maintained in long-term users.

Pharmacokinetics

Half-Life
4h
Bioavailability
SC: not formally disclosed; sufficient for once-daily 40 mg dosing
Tmax
~1 hour (SC)
Data Confidence
moderate

Source: Plasma elimination half-life of ~4 hours after subcutaneous administration in human clinical trials (PMID 29500292)

Pharmacokinetics: Active Dose Over Time

t½ = ~4 hours

Disclaimer: This curve is a simplified first-order exponential decay model. Actual pharmacokinetics vary based on injection site, individual metabolism, body composition, and other factors. Half-life values are approximate and based on available preclinical and clinical literature. Many research peptides lack formal human pharmacokinetic studies. This is for educational purposes only, not medical advice.

Molecular Profile

Amino Acids
4
Molecular Weight
639.8 Da
Sequence
RYKF
HydrophobicPolarPositiveNegativeSpecialHow we generate these icons
Identifiers

Who Should Consider SS-31 (Elamipretide)

  • Adults with age-related mitochondrial dysfunction seeking to restore cellular energy
  • Patients with Barth syndrome (FDA accelerated approval granted for this indication)
  • Individuals with primary mitochondrial myopathy experiencing exercise intolerance
  • Older adults with declining cardiac function related to mitochondrial impairment
  • Patients with heart failure with preserved ejection fraction (HFpEF) under clinical investigation
  • Adults interested in longevity interventions targeting the root cause of cellular aging

Related Peptides

What Changed for SS-31 (Elamipretide)

  1. Safety

    Corrected Oct 16, 2026: SS-31 pregnancy risk is unknown, not contraindicated; allergy and newborn benzyl alcohol warnings added, per the FORZINITY label.

    Before: No reproductive safety data exists; SS-31 contraindicated in pregnancy and breastfeeding; no allergic reaction warning; benzyl alcohol called no concern for adults; eosinophilia said to clear by week 16 to 20 After: Not a label contraindication: no human pregnancy data, no harm in rat and rabbit studies (8.1), breastfeeding weighed against need (8.2); the section 5.1 and 5.2 warnings stated; eosinophil counts back to baseline after 6 to 12 months of use or after stopping (6.1)

    What this does not mean: There are still no human pregnancy data, so the risk is unknown. The page had said no reproductive data existed; rat and rabbit studies found no harm to development (section 8.1).

    Source: FORZINITY (elamipretide) prescribing information (openFDA label record, SPL version 10, effective Dec 10, 2025) (opens in a new tab) · Saved copy

  2. Dosing

    Corrected Oct 16, 2026: FORZINITY is a ready 80 mg/mL solution, so its 40 mg dose is 0.5 mL drawn with nothing mixed in, per the FORZINITY label.

    Before: Aggressive 40 mg daily, the FORZINITY label dose, with no note on its form beside the vial and BAC water math After: Aggressive 40 mg daily, noted as the FORZINITY label dose: a ready 80 mg/mL solution, 0.5 mL drawn from the vial with nothing added

    What this does not mean: FORZINITY's label did not change. The 4, 10 and 40 mg tiers are unchanged, and the calculator's vial and BAC water math still applies to research-grade powder only.

    Source: FORZINITY (elamipretide) prescribing information (openFDA label record, SPL version 10, effective Dec 10, 2025) (opens in a new tab) · Saved copy

  3. Safety

    Corrected Oct 16, 2026: serious hypersensitivity is the one label contraindication; pregnancy (risk unknown) and severe renal impairment are not, per FORZINITY.

    Before: Pregnancy or breastfeeding listed as contraindicated for lack of reproductive safety data, severe renal impairment listed as a contraindication, and known hypersensitivity After: Serious hypersensitivity, the one label contraindication (sections 4 and 5.2); pregnancy and breastfeeding per sections 8.1 and 8.2; severe renal impairment as the half dose of sections 2.2 and 8.6

    What this does not mean: Pregnancy risk is still unknown, since there are no human data; rat and rabbit studies found no harm. Severe renal impairment halves the label dose to 20 mg. Research-grade powder has no safety testing of its own.

    Source: FORZINITY (elamipretide) prescribing information (openFDA label record, SPL version 10, effective Dec 10, 2025) (opens in a new tab) · Saved copy

  4. Dosing

    Corrected Oct 9, 2026: the 4 mg and 10 mg SS-31 tiers are community doses; the FORZINITY label dose is 40 mg once daily, per the FDA label.

    Source: FORZINITY (elamipretide) prescribing information (openFDA label record, SPL version 10, effective Dec 10, 2025) (opens in a new tab) · Saved copy

Peptide Schedule Research TeamReviewed Apr 7, 20269 Citations

References

  1. [1]Long-term efficacy and safety of elamipretide in Barth syndrome: 168-week open-label extension results of TAZPOWER (Genet Med 2024) (opens in a new tab)(n=12)PubMed (opens in a new tab)PubMed
  2. [2]Late-life restoration of mitochondrial function reverses cardiac dysfunction in old mice (eLife 2020) (opens in a new tab)PubMed (opens in a new tab)PubMed
  3. [3]MMPOWER-3: Efficacy and safety of elamipretide in individuals with primary mitochondrial myopathy: the MMPOWER-3 randomized clinical trial (Karaa et al., Neurology 2023) (opens in a new tab)(n=218)PubMed (opens in a new tab)PubMed
  4. [4]A phase 2/3 randomized clinical trial to evaluate elamipretide in Barth syndrome: TAZPOWER (Genet Med 2021) (opens in a new tab)PubMed (opens in a new tab)PubMed
  5. [5]FDA NDA 215244

Related Resources

Related Tools

Storage & Stability

Before Reconstitution
Community reports store sealed research-grade powder at -20°C. FORZINITY is a ready-to-use solution, not a powder. Refrigerate unopened FORZINITY vials at 2-8°C (36-46°F) and do not freeze them. After the first dose, keep an opened vial at 2-8°C or at 20-25°C (68-77°F), and discard it 8 days after first opening (label section 16.2).
After Reconstitution
No published stability data exist for reconstituted research-grade SS-31. Community reports keep the mixed vial at 2-8°C and use it within 28 days. Avoid repeated freeze-thaw cycles.
Temperature
2-8°C (36-46°F) once mixed (community reports)

Frequently Asked Questions

The 4 mg dose was studied in early Phase 2 heart failure trials (EMBRACE-HF) alongside 40 mg and showed meaningful effects at the lower amount. Community users have latched onto this as a "minimum effective dose" concept, reasoning that healthy aging individuals need far less than patients with confirmed mitochondrial dysfunction. No dose-finding trial has been done in healthy adults though.

Not exactly. The primary endpoints (6-minute walk test, total fatigue score) were not met in the 12-week crossover. FDA accelerated approval was based on knee extensor muscle strength improvement seen in the open-label extension: an intermediate biomarker, not a clinical outcome. Continued approval depends on a confirmatory trial.

In TAZPOWER, 100% of participants had injection site redness, 75% had pain, and 67% had induration. That's the primary tolerability concern. Community reports say it gets more manageable after the first few weeks, and rotating sites helps. Eosinophilia also occurs in most users during the first 90 days but typically normalizes without symptoms.

The FDA-approved product as of September 2025 is FORZINITY (NDA 215244), not ELZURA. Some databases reference an "ELZURA" FDA label URL that returns a 404 error. Use NDA 215244 / FORZINITY for current prescribing information. FORZINITY is a ready-to-use 80 mg/mL solution in a 280 mg/3.5 mL vial, so it is never mixed with BAC water (label sections 3 and 11).

The FDA label doesn't contraindicate it in renal impairment: it calls for a dose reduction to 20 mg/day for severe renal impairment (eGFR under 30, not on dialysis). That's a dose adjustment, not a contraindication. Standard renal function monitoring is appropriate.